Disseminated tuberculosis in 2 children with inflammatory bowel disease receiving infliximab

Pediatric Infectious Disease Journal

Volumn 33, Issue 7, 2014, Pages 779-781

  Cruz, Andrea T ^a   Karam, Lina B ^a   Orth, Robert C ^a   Starke, Jeffrey R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

interferon gamma release assay; latent tuberculosis infection; screening; tumor necrosis factor

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERFERON GAMMA RELEASE ASSAY; MALE; MILIARY TUBERCULOSIS; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; CASE REPORT; CHEMICALLY INDUCED; COMPLICATION; INFLAMMATORY BOWEL DISEASES; LATENT TUBERCULOSIS; PATHOLOGY; TUBERCULOSIS, MILIARY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; TUBERCULIN TEST; TUBERCULOSIS, MILIARY;

EID: 84902550643     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000286     Document Type: Article

References (12)

1. Sjöberg D, Holmström T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis. 2013;7:e351-e357.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
3. Toussi SS, Pan N, Walters HM, et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-? inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318-1330.
4. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of Tuberculosis. Morbid Mortal Wkly Rep. 2003;52: 1-77.
5. Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37-42.
6. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36:1185-1206.
7. Gwee A, Pantazidou A, Ritz N, et al. To x-ray or not to x-ray? Screening asymptomatic children for pulmonary TB: a retrospective audit. Arch Dis Child. 2013;98:401-404.
8. Debeuckelaere C, De Munter P, Van Bleyenbergh P, et al. Tuberculosis following anti-TNF therapy in inflammatory bowel disease, despite negative screening. J Crohns Colitis. 2014;8:550-557.
9. Schick B, Dolgin J. The influence of prednisone on the Mantoux reaction in children. Pediatrics. 1963;31:856-859.
10. Redelman-Sidi G, Sepkowitz KA. IFN-? release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188:422-431.
11. Meintjes G, Lawn SD, Scano F, et al.; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516-523.
12. Thampi N, Stephens D, Rea E, et al. Unexplained deterioration during antituberculous therapy in children and adolescents: clinical presentation and risk factors. Pediatr Infect Dis J. 2012;31:129-133.